Login to Your Account



Deal Worth Up To $53M

Tercica, Genentech Sign Combo HGH/IGF-1 Product Partnership

By Jennifer Boggs


Thursday, July 12, 2007
Five years after Tercica Inc. first acquired rights to Genentech Inc.'s insulin-like growth factor-1 (IGF-1) - for which it gained approval as Increlex in 2005 for short stature in children with primary IGF-1 deficiency - the two companies expanded their collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiency.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription